HOME >> BIOLOGY >> NEWS
How the Biotech Revolution Is Changing the Way We Fight Disease

In the fall of 2005, leading scientists from the National Cancer Institute announced the beginning of the cancer genome atlas project, a large-scale endeavor to map every gene implicated in cancer and the first step toward development of new therapies for treating this still baffling disease. This spin-off of the human genome project is only the latest exciting research advance in a decades-long quest to fully understand the biochemistry of the human body and thereby gain insights into the secrets of health, disease, and aging.

In the new book DNA: How the Biotech Revolution Is Changing the Way We Fight Disease (Prometheus Books, $26) biochemist and veteran lab researcher Frank H. Stephenson tells the compelling story of how scientists on many fronts are succeeding in the battle against disease.

According to Stephenson, efforts to understand the nature of disease, down to its component molecular foundation, have reached an unprecedented intensity. There is an excitement out there, an expectation, that we are but a little ways away from stopping cancer in its tracks, from curing diabetes, and from preventing afflictions such as Alzheimer's, AIDS, and malaria, he says. There is the sense that each gene we discover, each molecular pathway we elucidate brings us closer to cures.

With a gift for making the complexities of genetics and biochemistry understandable to the average reader, Stephenson offers a fascinating tour of the mechanisms of our body and the therapeutic techniques that are gaining in sophistication and effectiveness every year. From heart disease to AIDS and cancer, he helps you understand how the tools of biotechnology are being used to combat our most common afflictions. Stephenson examines a wide variety of health threats and illnesses: HIV infection, the many forms of cancer, asthma, diabetes, Alzheimers, obesity, and even erectile dysfunction. Each is discussed in terms of its root cause and treatment in pla
'"/>

Contact: Lynn Pasquale
Lpasquale@prometheusbooks.com
800-853-7545
Prometheus Books
18-Jun-2007


Page: 1 2

Related biology news :

1. Biotech breakthrough could end biodiesels glycerin glut
2. Rutgers: GM/GMO/Biotech crop containment strategy
3. Ronald Cape to receive 2007 Biotechnology Heritage Award
4. Oncolytics Biotech Inc., research collaborators demonstrate reovirus/gemcitabine
5. Oncolytics Biotech Inc. proceeds to initiate US Phase II sarcoma clinical trial
6. Biotechnology Study Center honors Joan V. Ruderman, Salvador Moncada and Charles N. Serhan
7. European Federation of Biotechnology and Elsevier announce launch of biotechnology journal
8. Advances in Optics for Biotechnology, Medicine and Surgery
9. Biolex reports potential for more potent, efficacious antibodies in Nature Biotechnology
10. Developing uses for sugar-cane bagasse: Biotechnology applied to the paper industry
11. Biotech cotton provides same yield with fewer pesticides

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/2/2017)... YORK , Feb. 2, 2017  EyeLock LLC, ... released a new white paper " What You Should ... The problem of ensuring user authenticity is a growing ... the authentication of users. However, traditional authentication schemes such ... Biometric authentication offers an elegant solution ...
(Date:1/30/2017)... FRANCISCO , Jan. 30, 2017   Invitae ... the fastest growing genetic information companies, today announced that ... financial results and provide 2017 guidance on Monday, February ... conference call that day at 4:45 p.m. Eastern / ... Invitae,s management team will briefly review financial results, guidance, ...
(Date:1/24/2017)... 2017 Biopharm Reports has carried out ... of nuclear magnetic resonance spectroscopy (NMR). This involved ... current practices, developments, trends and end-user plans over ... and opportunities. These areas include growth in the ... and innovation requirements, hyphenated NMR techniques, main suppliers ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... LOS ANGELES , Feb. 16, 2017 /PRNewswire/ ... CAPR ), a clinical-stage biotechnology company developing first-in-class ... today announced that it has elected to terminate ... to natriuretic peptide receptor agonists, including Cenderitide. ... a strategic move as we prioritize our efforts ...
(Date:2/16/2017)... PALM BEACH, Florida , February 16, 2017 ... vastly improving with the infusion of innovative telemedicine ... patient monitoring services that are experiencing a boom ... evolve with the advancement of technologies, services and ... Technologies Inc. (OTC: RQHTF) (TSX-V: RHT), Cellectar Biosciences, ...
(Date:2/16/2017)... Feb. 16, 2017  Dermata Therapeutics, LLC, a ... treat a variety of dermatological diseases, today announced ... financing and entered into a $5 million credit ... to use the capital for general corporate purposes ... in the treatment of serious diseases treated by ...
(Date:2/16/2017)... , ... February 16, 2017 , ... ... case. Dr. Kingsley Chin, professor and Harvard trained surgeon, completed the procedure on ... performed on a 55-year-old practicing female physician suffering from degenerative disc disease with ...
Breaking Biology Technology:
Cached News: